Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
VRDN · Why this verdict
Why Viridian Therapeutics (VRDN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company burns cash at a rate where free cash flow is negative 257% of revenue, and the entire pipeline is concentrated in a single program (veligrotug), making financial sustainability entirely dependent on one clinical outcome. Quality breakdown | Over 12 months, cash burn as a percent of revenue should narrow meaningfully as revenue grows 96% year-over-year, reducing the single-program concentration risk. | →Stable |
| CounterA single clinical setback in veligrotug would eliminate the investment thesis entirely, and the current cash runway may force a dilutive equity raise before any catalyst. | ||
Analysts assign a price target implying 108% upside from the current $16.30, with a sentiment score of 8.3 out of 10, suggesting institutional conviction that the single-program risk is already priced into the stock. Sentiment breakdown | Analyst price targets should remain at or above $30 and buy ratings should be maintained or increased as clinical data matures over the next 12 months. | →Stable |
| CounterAnalyst coverage may be thin or conflicted, and a 108% upside estimate in a cash-burning biotech often reflects speculative target-setting rather than near-term achievable value. | ||
The company has beaten earnings estimates in 3 of the last 4 quarters with an average positive surprise of 18.8%, including a 63.9% beat in Q3 2025, suggesting the management team is effectively managing expectations. Earnings | Earnings surprises should remain positive — at least 0% surprise — in at least 3 of the next 4 quarters, maintaining the beat streak that supports sentiment. | →Stable |
| CounterEarnings beats in a company reporting losses reflect moving loss estimates rather than fundamental progress, and the one miss of -7.96% in Q1 2026 shows the trajectory is not guaranteed. | ||
Short interest stands at 14% of the float with an elevated put/call ratio of 1.39, indicating significant bearish positioning against the stock that could fuel a short squeeze if clinical news is positive. Key risks | Short interest should decline below 10% over 12 months as positive clinical developments reduce the bear thesis and reduce the put/call ratio toward 1.0. | →Stable |
| CounterHigh short interest is frequently a rational response to company-specific risk in single-asset biotechs, and a short squeeze alone does not create lasting value without clinical success. | ||
The company burns cash at a rate where free cash flow is negative 257% of revenue, and the entire pipeline is concentrated in a single program (veligrotug), making financial sustainability entirely dependent on one clinical outcome.
→StableQuality breakdown
- Expectation
- Over 12 months, cash burn as a percent of revenue should narrow meaningfully as revenue grows 96% year-over-year, reducing the single-program concentration risk.
CounterA single clinical setback in veligrotug would eliminate the investment thesis entirely, and the current cash runway may force a dilutive equity raise before any catalyst.
Analysts assign a price target implying 108% upside from the current $16.30, with a sentiment score of 8.3 out of 10, suggesting institutional conviction that the single-program risk is already priced into the stock.
→StableSentiment breakdown
- Expectation
- Analyst price targets should remain at or above $30 and buy ratings should be maintained or increased as clinical data matures over the next 12 months.
CounterAnalyst coverage may be thin or conflicted, and a 108% upside estimate in a cash-burning biotech often reflects speculative target-setting rather than near-term achievable value.
The company has beaten earnings estimates in 3 of the last 4 quarters with an average positive surprise of 18.8%, including a 63.9% beat in Q3 2025, suggesting the management team is effectively managing expectations.
→StableEarnings
- Expectation
- Earnings surprises should remain positive — at least 0% surprise — in at least 3 of the next 4 quarters, maintaining the beat streak that supports sentiment.
CounterEarnings beats in a company reporting losses reflect moving loss estimates rather than fundamental progress, and the one miss of -7.96% in Q1 2026 shows the trajectory is not guaranteed.
Short interest stands at 14% of the float with an elevated put/call ratio of 1.39, indicating significant bearish positioning against the stock that could fuel a short squeeze if clinical news is positive.
→StableKey risks
- Expectation
- Short interest should decline below 10% over 12 months as positive clinical developments reduce the bear thesis and reduce the put/call ratio toward 1.0.
CounterHigh short interest is frequently a rational response to company-specific risk in single-asset biotechs, and a short squeeze alone does not create lasting value without clinical success.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Viridian Therapeutics is a high-risk, single-asset biotech trading at $16.30 with 96% revenue growth but critically weak business quality (quality score 1.6), heavy cash burn at negative 257% free cash flow relative to revenue, and 14% short interest — the stock offers high asymmetry upside to $30.54 only if it can close its quality gap and sustain clinical momentum.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -257% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 96% YoY
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.5 |
| Volume | 2.1 |
- ▸Overbought bear rally (RSI 79)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
8.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.1 |
| Analyst rating | 8.7 |
| Price target | 9.9 |
- ▸LLM news sentiment: +0.62 (n=5)
- ▸Analyst upside: 86%
Insider
7.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| holder change | 5.1 |
- ▸Heavy insider buying — $19,999,990 (0.934% of mkt cap)
Peer rank
3.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.0 |
| quality rank | 1.9 |
| growth rank | 8.1 |
- ▸Industry growth leader
Technical
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.3 |
| 52w position | 1.3 |
| gap | 5.0 |
Risk (lower is worse)
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.9 |
| days to cover | 1.1 |
| volatility | 1.3 |
| put call | 9.6 |
| implied vol | 0.3 |
| beta | 7.6 |
| debt equity | 0.0 |
| news risk | 5.0 |
- ▸High IV: 78%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.2>=5.5
- ASYMMETRY:4.5>=1.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.50
- NEWS_BOOST:ANALYST_CLUSTER(3)
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=6.2>=5.0 recovering
- 8K_FLAG:1.02
Reward-to-Risk
4.51
Upside
+67.6%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 79
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -43% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Sentiment at 8.9, and Insider at 7.0; the weakest are Technical at 1.6, Quality at 1.6, and Peer rank at 3.1. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 4.51 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn Pipeline Concentration
Trip ifCash burn rate stays above negative 200% of revenue for more than 2 consecutive quarters, or the company announces a dilutive equity raise at a price below $14.
- P2Analyst Sentiment Upside
Trip ifConsensus analyst price target falls below $25, more than 20% below the current target of $30.54.
- P3Earnings Beat Trajectory
Trip ifEPS surprise falls below 0% in at least 3 of the next 4 quarters.
- P4High Short Interest Squeeze Risk
Trip ifShort interest rises above 20% of float or put/call ratio exceeds 2.0.